BIOMAT Database Logo BIOMAT Database Logo

Effect of recombinant human erythropoietin on the anemia of chronic renal failure. 1988

A Urabe, and F Takaku, and H Mizoguchi, and K Kubo, and K Ota, and N Shimizu, and K Tanaka, and N Mimura, and H Nihei, and S Koshikawa
Third Department of Internal Medicine, Faculty of Medicine, University of Tokyo, Japan.

Phase I and Phase II studies of recombinant human erythropoietin (rhEpo) were conducted in normal volunteers and in anemic patients with chronic renal failure on maintenance hemodialysis. Three hundred U/person of rhEpo was administered intravenously to healthy normal volunteers in the Phase I study, resulting in no subjective or objective changes. In the Phase II study, 66 patients with chronic renal failure on maintenance hemodialysis with less than 20% hematocrit values were treated with rhEpo in doses of 50 U/kg to 200 U/kg two or three times a week. Hematocrit values increased significantly during the 12 weeks, and the patients' conditions improved. Patients previously requiring blood transfusions became transfusion-independent during our study. There were no obvious side effects, thus indicating the safety and efficacy of rhEpo in the anemia of chronic renal failure.

UI MeSH Term Description Entries
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D004921 Erythropoietin Glycoprotein hormone, secreted chiefly by the KIDNEY in the adult and the LIVER in the FETUS, that acts on erythroid stem cells of the BONE MARROW to stimulate proliferation and differentiation.
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

A Urabe, and F Takaku, and H Mizoguchi, and K Kubo, and K Ota, and N Shimizu, and K Tanaka, and N Mimura, and H Nihei, and S Koshikawa
Recombinant erythropoietin for the anemia of chronic renal failure.
July 1987, The New England journal of medicine,
A Urabe, and F Takaku, and H Mizoguchi, and K Kubo, and K Ota, and N Shimizu, and K Tanaka, and N Mimura, and H Nihei, and S Koshikawa
Treatment of the anemia of chronic renal failure with recombinant human erythropoietin.
January 1990, Annual review of medicine,
A Urabe, and F Takaku, and H Mizoguchi, and K Kubo, and K Ota, and N Shimizu, and K Tanaka, and N Mimura, and H Nihei, and S Koshikawa
[The effect of low doses of recombinant human erythropoietin on renal anemia in predialysis patients with chronic renal failure].
July 1993, Zhonghua nei ke za zhi,
A Urabe, and F Takaku, and H Mizoguchi, and K Kubo, and K Ota, and N Shimizu, and K Tanaka, and N Mimura, and H Nihei, and S Koshikawa
Treatment of the anemia of chronic renal failure with subcutaneous recombinant human erythropoietin.
October 1990, The American journal of medicine,
A Urabe, and F Takaku, and H Mizoguchi, and K Kubo, and K Ota, and N Shimizu, and K Tanaka, and N Mimura, and H Nihei, and S Koshikawa
[The observation of therapy of anemia in chronic renal failure with recombinant human erythropoietin].
February 1994, Zhonghua nei ke za zhi,
A Urabe, and F Takaku, and H Mizoguchi, and K Kubo, and K Ota, and N Shimizu, and K Tanaka, and N Mimura, and H Nihei, and S Koshikawa
The anemia of chronic renal failure: pathophysiology and effects of recombinant erythropoietin.
January 1990, Contributions to nephrology,
A Urabe, and F Takaku, and H Mizoguchi, and K Kubo, and K Ota, and N Shimizu, and K Tanaka, and N Mimura, and H Nihei, and S Koshikawa
Anemia of chronic renal failure: characterization in the mouse and correction with human recombinant erythropoietin.
January 1996, Nephron,
A Urabe, and F Takaku, and H Mizoguchi, and K Kubo, and K Ota, and N Shimizu, and K Tanaka, and N Mimura, and H Nihei, and S Koshikawa
Iron balance following recombinant human erythropoietin therapy for anemia associated with chronic renal failure.
June 1991, International journal of hematology,
A Urabe, and F Takaku, and H Mizoguchi, and K Kubo, and K Ota, and N Shimizu, and K Tanaka, and N Mimura, and H Nihei, and S Koshikawa
The anemia of chronic renal failure: pathophysiology and the effects of recombinant erythropoietin.
January 1989, Kidney international,
A Urabe, and F Takaku, and H Mizoguchi, and K Kubo, and K Ota, and N Shimizu, and K Tanaka, and N Mimura, and H Nihei, and S Koshikawa
Treatment of the anemia of progressive renal failure with recombinant human erythropoietin.
July 1989, The New England journal of medicine,
Copied contents to your clipboard!